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Abstract
Introduction: Biological studies in animals and epidemiological findings in humans clearly demonstrate that
estrogens including 17β-estradiol (E2) are weak carcinogens via both genetic and epigenetic mechanisms.
Carcinogenesis analyses have indicated that female mice exposed to E2 as neonates develop more mammary and
ovarian tumors when compared to adult exposures. In the present study, Big Blue transgenic mice were used to
investigate the effects of E2 on mutagenicity of 7,12-dimethylbenz [a] anthracene (DMBA), a genotoxic carcinogen,
in mammary gland and ovary following neonatal exposure.
Results: DMBA treatment resulted in significant increases in cII mutant frequencies (MFs) in both mammary glands
and ovaries, with A:T→ T:A transversion as the predominant type of mutation. However, co-exposure to E2 daily for
the first 5 days after birth and to DMBA at 6 months of age did not significantly increase cII MFs compared to
DMBA treatment alone. Further, there were also no significant differences in mutational spectra between DMBA
exposure alone and E2 + DMBA treatment.
Conclusion: These results suggest that early life exposures of mice to estrogens like E2 do not enhance
mutagenicity by subsequent exposure to a chemical like DMBA in later life.
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Introduction
Estrogens are mainly known for their roles in female re-
productive tissues, but also have a vast array of functions
in other tissues, including adipose tissue, bone, brain,
skeletal muscle, skin, and the vasculature [1]. Human
exposure to low doses of endogenous estrogens, estro-
genic drugs, phytoestrogens, and xenoestrogens has the
potential to improve health or disrupt normal endocrine
activity [2]. 17β-estradiol (E2), as the primary endogen-
ous estrogen produced in the ovary in premenopausal
women, profoundly effects sexual differentiation, repro-
ductive function, and behavior; in addition to other
activities, such as regulating lipid profiles and the levels
of blood clotting factors. E2 has been used for hormone
replacement therapy in postmenopausal women, as it
can remit menopause symptoms and improve the quality
of life for many women [3]. However, numerous studies
have suggested that there are increased risks for breast
and ovarian cancers associated with hormone replace-
ment therapy [4, 5].
Animal studies and epidemiological findings in humans
clearly demonstrate that estrogens, including E2, are weak
carcinogens via both genetic and epigenetic mechanisms
[6]. It has been reported that E2 induces DNA damage
and causes a relatively low frequency of gene mutations,
and the genotoxic activity of E2 is most likely induced by
catecholestrogen metabolites after metabolic activation
[7]. The effects of estrogens appear to be tissue-specific, as
tumor induction is primarily in the uterus, mammary
glands, and ovaries. Carcinogenesis studies have indicated
that female mice exposed to E2 as neonates developed
more mammary and ovarian tumors when compared to
adult exposure [8, 9]. In addition, E2 promotes the devel-
opment of hepatic neoplasms in rats [10, 11].
It has been reported that exposure to chemicals
(i.e., endocrine disrupting chemicals interfering with
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the body’s endocrine system) during early stages of
development can disrupt normal patterns of develop-
ment and alter disease susceptibility later in life [12].
About three decades ago, a concern was expressed
about the levels of phytoestrogens in soy infant-
formula presenting the risk of adverse effects. High
circulating levels of genistein have been determined
in infants fed soy-based formulas [13]. It has been
reported that neonatal exposure to genistein disrupts
the female mouse reproductive tract and subsequently
contributes to infertility [14]. However, there is lim-
ited information regarding long-term effects of infant
exposure to soy-based infant formulas, and the effect
of early life exposures to phytoestrogens on animal
susceptibility to subsequent chemical insults in later
life [15].
Previously, we evaluated 7,12-dimethylbenz [a] anthra-
cene (DMBA)-induced mutagenicity in the heart, mam-
mary gland, and uterine tissues as well as DMBA-induced
carcinogenicity in the mammary and uterine dysplasia in
both ovariectomized (OVX) and ovary intact (INT),
7 week-old Big Blue transgenic rats fed E2 and soy isofla-
vones for up to 20 weeks [16–18]. Although feeding
isoflavones or E2 did not cause any significant changes in
the DMBA-induced mutagenicity in the mammary or
uterus of both OVX and INT rats, there were significant
increases in the incidence of ductal hyperplacia and aden-
oma/adenocarcinoma in the mammary gland of INT Big
Blue rats and dysplasia in the uterus of OVX rats fed E2
or isoflavones with or without DMBA. However, unlike
the reproductive tissues, where E2 was not beneficial, the
DMBA-induced mutagenicity in the heart was signifi-
cantly modulated by E2 suggesting a beneficial effect [17].
In this study, using E2 as a model estrogen, we investi-
gated whether or not neonatal exposure to E2 modifies
the mutant frequency (MF) in Big Blue mice treated at




DMBA and E2 were purchased from Sigma (St. Louis,
MO). The RecoverEase DNA Isolation Kit, Transpack
packaging extract, and the Escherichia coli G1250
strain were obtained from Agilent Technologies (Santa
Clara, CA). PCR Master Mix was purchased from
Promega (Madison, WI), and CEQ Dye Terminator
Cycle Sequencing kits were obtained from Beckman
Coulter (Fullerton, CA).
Animals and treatments
During the course of animal experiment, we followed the
recommendations set forth by our Institutional Animal
Care and Use Committee for the handling, maintenance,
treatment, and sacrifice of the animals. Six pregnant
female Big Blue C57BL/6 transgenic mice (homozygous
for the transgene) were obtained from Taconic Farms
(Germantown, NY). These mice were bred with non-
transgenic C3H male mice by the supplier. Twenty fe-
male B6C3F1 offspring (heterozygous for the transgene)
were pooled and randomly divided into 4 groups at
birth (i.e., 5 mice in each group). Six to eight pups were
assigned to each foster mother [19]. Pups of two groups
(i.e., 10 pups) were given 10 mg E2 per kg body weight
by subcutaneous injection on each of the first 5 days of
life and two groups were not treated. After weaning, the
mice were fed NIH-31IR diet (Purina Mills, Brentwood,
MO). At 6 months of age, the mice in one group each
with or without neonatal exposure to E2 were treated with
20 mg DMBA per kg body weight by gavage twice within
a week. Our dose choice of E2 or DMBA was based on
previous studies where DMBA alone resulted in signifi-
cant increases in gene mutant frequencies [20, 21] while
E2 alone aderministered for up to 2 years induced tumors
in various organs of mice [22], and combined treatment
with E2 and DMBA induced more ovarian tumors [8]. Six
weeks after DMBA treatment, the mice in the four groups
were sacrificed, and the mammary glands and ovaries
were isolated, frozen quickly in liquid nitrogen, and stored
at −80 °C for later assays of cII mutations.
cII mutant assay
High molecular-weight genomic DNA was extracted from
ovaries and mammary glands using the RecoverEase DNA
Isolation Kit [23] and the cII mutagenicity assay was
performed using the method previously described [24].
Sequence analysis of cII mutants
The cII mutant plaques from control and treated mice
were isolated and sequenced as previously reported [25].
Statistical analyses
Analyses were performed using SigmaStat 11.0 (Systst
Software Inc., San Jose, CA). Data are expressed as the
mean ± standard error of mean (SEM) from 3 or 5 mice
per group. Statistical significance was determined by
one-way analysis of variance (ANOVA) followed by the
Holm-Sidak test for comparison of multiple treatment
groups. Mutation spectra were compared using the
computer program written by Cariello et al. [26] for the
Monte Carlo analysis developed by Adams and Skopek [27].
Results
Mutant frequency
MFs were determined for the mammary and ovary cII
gene of the Big Blue mice treated with DMBA at
6 months with or without neonatal exposure to E2
(Fig. 1). For the mammary gland, the MF of the control
Zhang et al. Genes and Environment  (2015) 37:16 Page 2 of 6
group was 52.6 ± 9.8 (SEM) × 10−6. The MF in the E2
group was 79.9 ± 15.2 × 10−6, which was slightly higher
than the unexposed control group but not significantly
different (ANOVA, Holm-Sidak test). The MFs in the
DMBA and E2 + DMBA groups were 268.9 ± 63.1 × 10−6
and 276.6 ± 48.6 × 10−6, respectively, which were signifi-
cantly higher than that of the unexposed control group
and the E2 alone group (p < 0.05). In the ovary, the MFs
of the DMBA and E2 + DMBA groups were 366.2 ±
78.1 × 10−6 and 408.7 ± 54.3 × 10−6, respectively; both
significantly higher than that of the unexposed control
(54.3 ± 1.2 × 10−6) and E2 only group (75.8 ± 15.0 × 10−6).
There was no significant difference between the E2-only
group and the control group. These results indicate that
DMBA induced significant increases in cII MF both in
the mammary gland and ovary and that the neonatal
exposure to E2 did not affect the mutation induction by
DMBA in the two tissues.
Mutation analysis
We examined the types of mutations induced by DMBA
with or without neonatal exposure to E2 in mammary
glands and ovary tissues. The cII gene mutations in the
mammary gland were analyzed by DNA sequencing
(Additional file 1: Table S1); and 33 independent muta-
tions were identified from the control group, 40 from
the E2-only group, 66 from the DMBA group, and 91
from the E2 + DMBA group (Table 1). A pairwise
multiple comparisons of these mutational spectra were
performed [28]. There were significant differences in the
type of mutations between the DMBA and control
groups. Also, the mutations in the E2 + DMBA group
and the E2-only group differed significantly (p < 0.001).
However, there were no significant differences between
the E2-only and unexposed control groups (p = 0.90), and
between the DMBA and E2 +DMBA groups (p = 0.99).
Among the mutations, the major type of mutation was
G:C→A:T transition in the unexposed control (43 %)
and E2 treated (45 %) groups, whereas a A:T→T:A trans-
version was the predominant mutation in the DMBA
(50 %) and E2 + DMBA (53 %) groups (Table 1). We also
conducted DNA sequence analysis of the ovary cII gene
(Additional file 1: Table S2). We identified 38 independent
mutations from the control group, 25 from the E2-only
group, 98 from the DMBA group, and 114 from the E2 +
DMBA group (Table 1). Consistent with that of mammary
tissue, there was a significant difference in the types of
mutations between E2 + DMBA group and E2-only group
(p < 0.01). The types of mutations in the DMBA group
and control group also differed significantly (p = 0.004).
However, there were no significant differences between
the E2 and unexposed control groups (p = 0.92), and
between the DMBA and E2 +DMBA groups (p = 0.62).
The most common type of mutations induced by
DMBA in the ovary was also A:T→ T:A transversion,
which accounted for 38 % and 33 % of mutations in the
DMBA and E2 + DMBA groups, respectively. Whereas
G:C→A:T transition was the major type of mutation
in the unexposed control (42 %) group and E2-only
(44 %) group, respectively (Table 1).
Discussion
Breast cancer is the most common cancer (25.1 %) in
women globally, while ovarian cancer is the 7th most
common cancer (3.6 %) [29]. Since 2000, breast cancer
incidence in the U.S. has decreased, partially due to the
reduced use of hormone replacement therapy. However,
it remains the leading cause of cancer deaths in American
women with about 40,000 deaths each year [30]. In 2014,
there were 22,000 new cases of ovarian cancer in the U.S.,
with about 14,270 deaths in 2014 [31]. Among various
factors related to reproductive cancers, endogenous estro-
gens and exogenous hormones are the key risk factors.
Chemicals with estrogenic activity are derived from
thousands of natural and synthetic processes; therefore,
human exposure to estrogenic chemicals is ubiquitous
[2]. Soy infant formula containing phytoestrogens has
been fed to infants for ~60 years as a supplement to or
replacement for human milk or cows’ milk. Recently, the
concerns for the reproductive and developmental
toxicity of soy infant formula have been raised, and one
of numerous data gaps is that early life exposure to phy-
toestrogens may alter risk for hormonally dependent
diseases, such as breast cancer [15]. In addition, it has
been suggested that prenatal or neonatal exposure to
endocrine-disrupting compounds can alter the hormonal
Fig. 1 Mutant frequencies in the cII gene in mammary gland and
ovary of mice. Big Blue transgenic mice were exposed to E2 during
the first 5 days of life and/or treated with DMBA at 6 months of age.
Significant differences were found between DMBA and control
groups, between E2 + DMBA and control groups, between DMBA
and E2-only groups, and between E2 + DMBA and E2-only groups,
respectively, for the both tissues (* p < 0.05 and ** p < 0.01). The data
represent the mean ± S.E.M. from 3 ~ 5 mice in each group
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milieu, reproductive tissue development, and susceptibil-
ity to potential carcinogen exposure in adults [32].
DMBA, a polycyclic aromatic hydrocarbon and a model
carcinogen, has been extensively used in experimental car-
cinogenesis studies. Previously, we demonstrated that ge-
nistein, an alternative to hormone replacement therapy in
postmenopausal women, showed no effects on DMBA-in-
duced mutagenicity in livers [11], mammary glands [18],
and uterus in Big Blue transgenic rats [16]. In this study,
Big Blue transgenic mice were injected subcutaneously
with E2 on the first 5 days of their life and then received
DMBA at age of 6 months. For both mammary gland and
ovary tissues, there were no significant differences in MFs
in the cII gene between the control and E2-only groups,
and between the two DMBA groups with or without neo-
natal exposure to E2; however, the DMBA treatment
groups showed significantly higher MFs than the control
and E2 alone groups (Fig. 1). Similarly, we also observed
similar patterns of mutation spectra, with A:T→ T:A
transversions as the predominant mutation in the
DMBA-treated groups compared to G:C→A:T transi-
tions as the main mutation in the control and E2-only
groups (Table 1). These results indicate that DMBA
induced significant cII MFs both in the mammary gland
and ovary tissues; however, neonatal exposure to E2 did
not significantly affect the mutagenicity induced by
DMBA exposure in later life both in the mammary
gland and ovary of Big Blue mice. These results indicate
that under the experimental conditions used in this
study, elevated levels of estrogen in neonates do not
promote chemical-induced mutations in adults.
When female C3/129 mice were given E2 injections
for the first 5 days after birth and gastric intubations of
DMBA at an age of 70 days, more ovarian tumors
(78 %) of the granulose cell type were observed at the
age of 1 year compared to those in DMBA alone group
(33 %) [8]. In addition, about 59 % of mice developed tu-
mors at 20 weeks of age, whereas no mice had ovarian
tumor in the DMBA-alone group. Similar results also
were observed in the incidence of mammary dysplasia in
BALB/c mice [9]. Recently, soy diet has been found to
promote granulose cell tumors in C57BL/6 J/129S7/Sv
mixed mice [33]. Although there is genetic variation in
physiological sensitivity to E2 between strains of mice,
C57BL/6 is one of mouse strains that are highly respon-
sive to E2 [34, 35]. Our results for the cII MFs in female
Table 1 Summary of independent cII mutations in mammary gland and ovary of Big Blue transgenic mice exposed to E2 at the first
5 days of life and/or treated with DMBA at 6 months of age
Tissue Type of mutation Control E2a DMBAb E2 + DMBAc, d
Number % Number % Number % Number %
Mammary gland G:C→ C:G 3 9 4 10 4 6 4 4
G:C→ A:T 14 43 18 45 5 8 8 9
G:C→ T:A 7 21 6 15 13 20 14 16
A:T→ T:A 1 3 4 10 33 50 48 53
A:T→ C:G 3 9 3 8 3 4 4 4
A:T→ G:C 2 6 1 2 5 8 9 10
Frameshift 3 9 4 10 3 4 3 3
Tandem 0 0 0 0 0 0 1 1
Total mutants
screened
33 100 40 100 66 100 91 100
Ovary G:C→ C:G 2 5 2 8 11 11 13 11
G:C→ A:T 16 42 11 44 12 12 19 17
G:C→ T:A 9 24 6 24 22 23 20 17
A:T→ T:A 3 8 1 4 37 38 37 33
A:T→ C:G 1 3 1 4 5 5 6 5
A:T→ G:C 2 5 0 0 9 9 10 9
Frameshift 5 13 4 16 2 2 7 6
Tandem 0 0 0 0 0 0 2 2
Total mutants screened 38 100 25 100 98 100 114 100
aNo significant difference from control group
bSpectrum from DMBA-treated mice was significantly different from control and E2-only groups (p < 0.0001)
cSpectrum from the mice exposed to E2 and DMBA was significantly different from control and E2-only groups (p < 0.01 in ovary and p < 0.0001 in
mammary gland)
dNo significant difference from DMBA group
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B6C3F1 mice (C57BL/6 as one of the parental strains)
were not directly correlated with the incidences of breast
or ovarian tumors, suggesting that induction of tumors
by early exposure to estrogens is not via increasing
mutagenicity; thus other factors associated with the
initiation, promotion, and progression of cancers may be
involved. Although many aspects are still unknown,
estrogen receptor-mediated effects on cell proliferation
contribute to the weight of evidence for estrogen-
mediated cancer [36]. It has been reported that genistein
modulates estrogen-receptor expression and signaling in
COV434 cells derived from a primary human juvenile
granulose cell tumor, promoting cell growth [33]. In
addition, the nature of genetic differences in mouse
strains and subspecies is a major source of variation in
susceptibility to endocrine disruption by estrogens [37].
Conclusion
In 2008, the National Toxicology Program (NTP)
reported that there was some evidence (or equivocal
evidence) of carcinogenic activity of genistein in female
rats, with acceleration of the onset of aberrant estrous
cycles when rats were continuously exposed to genis-
tein from conception through weaning (21-day-old),
20 weeks, and 2 years, respectively, and all rats were
sacrificed after 2-year study [38]. Regarding soy infant
formula containing phytoestrogens, there was insufficient
data on reproductive toxicity in humans and animals [39]
and recently, a NTP expert panel has summarized critical
data gaps and research needs on pharmacokinetics,
human epidemiology, and experimental animals [15]. The
results in this study demonstrates that neonatal exposure
to E2 did not affect the mutagenicity in mammary gland
and ovary induced by DMBA in mice, and provides a
piece of information concerning the effect of early life
exposures to estrogens on the mutagenicity or carcinogen-
icity of subsequent chemical insults in later life.
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